CARsgen's CAR T MM therapy shows early signs of efficacy in Phase I trial [Yahoo! Finance]
Pfizer, Inc. (PFE)
Last pfizer, inc. earnings: 4/28 06:45 am
Check Earnings Report
US:NYSE Investor Relations:
investors.pfizer.com/investors-overview/default.aspx
Company Research
Source: Yahoo! Finance
CT071 is CAR T cell drug that acts by binding to cells expressing GPRC5D. It was developed using CARsgen's CARcelerate platform for the treatment of patients with RRMM or plasma cell leukaemia. Preliminary data from the Phase I trial (NCT05838131) was shared during the 29th Annual Congress of the EHA, which took place in Madrid, Spain on 13–16 June. The first in human study is a single-arm, open-label trial with a primary endpoint of safety and tolerability. The trial is also investigating dose range and early signs of efficacy. Investigators had dosed ten patients as of the 28 February data cut off, seven at a low dose and three at high dose. The overall response rate (ORR) was 90%. Five patients showed stringent complete response, two had very good partial response and two had partial response. Pharmacokinetic analysis showed robust cell expansion and persistence after dosing. As of the data cut-off, CARsgen observed no Grade 3 adverse events. There were also no events of
Show less
Read more
Impact Snapshot
Event Time:
PFE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PFE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PFE alerts
High impacting Pfizer, Inc. news events
Weekly update
A roundup of the hottest topics
PFE
News
- Is Pfizer's Pain Sarepta Therapeutics' Gain? Don't Bet on It. [Yahoo! Finance]Yahoo! Finance
- Moderna says its RSV shot is 50% effective after 18 months [CNBC]CNBC
- Obesity Pipeline Research 2024: Insights About 80+ Companies and 100+ Pipeline Drugs - Therapeutics Assessment by Product Type, Stage, Route of Administration, and Molecule Type [Yahoo! Finance]Yahoo! Finance
- Capvaxive will enhance protection against pneumococcal disease in older adults [Yahoo! Finance]Yahoo! Finance
- Meet The University College London (UCL) School Of Management MBA Class Of 2025 [Yahoo! Finance]Yahoo! Finance
PFE
Earnings
- 5/1/24 - Beat
PFE
Sec Filings
- 6/17/24 - Form 4
- 6/17/24 - Form 4
- 6/11/24 - Form 11-K
- PFE's page on the SEC website